At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 337 enrolled
Drug / intervention
E3810 +2 moredrug
Likely dose
E3810 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
In Brief
A Phase 3 clinical trial evaluating E3810 for Refractory Reflux Esophagitis. Completed, enrolled 337 participants across 54 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Reflux Esophagitis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedOct 2008
Primary CompletionNov 2009
Study CompletionMar 2010
TodayJul 2026
First PostedOct 10, 2008
Enrollment StartOct 1, 2008
Primary CompletionNov 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.7 years ago
Interventions
E3810drug
20 mg taken orally, once a day for 8 weeks.
E3810drug
10 mg, taken orally, twice a day for 8 weeks.
E3810drug
20 mg taken orally, twice a day for 8 weeks.